Skip to content Skip to sidebar Skip to footer

Biogen CEO’s tight-lipped zuranolone commentary not enough for Sage investors


Analysts and investors wanted the tea on the FDA review of Sage Therapeutics’ zuranolone, but Biogen CEO Chris Viehbacher wouldn’t spill it. | Analysts and investors wanted the tea on the FDA review of Sage Therapeutics’ zuranolone, but Biogen CEO Chris Viehbacher wouldn’t spill it.


Leave a comment